

# 2021 Research Program Overview



From our very first 5K event which funded one grant in 2008, Lung Cancer Initiative (LCI) has been committed to advancing lung cancer research as the most critical way to save lives. Based in North Carolina, LCI is fortunate to collaborate with medical leaders and renowned medical institutions from across the state. The Scientific Advisory Committee provides leadership for the organization's research fellowships and other research grants including health disparities in lung cancer and career development.

**\$2.6M**

Total funded in  
lung cancer research

**50**

Total researchers  
funded



## LCI Fellows Program

Initiated in 2015, the LCI Fellows Program provides research funding for students who wish to pursue a career in lung cancer research, diagnosis, treatment and/or care. Our Fellowship partners include researchers from Duke University, East Carolina University, University of North Carolina at Chapel Hill, Wake Forest University and Levine Cancer Institute.

**\$25K**

Total provided  
per project,  
per year

**34**

Fellows funded  
to date

**85%**

Fellows continuing  
in the field  
of lung cancer



## Supporting Innovation

Through the Vicky Amidon Innovation in Lung Cancer Research Award established in 2018, LCI recognizes and supports researchers, industry partners and collaborations aimed toward developing innovative lung cancer projects that will improve the lives of those at risk of or with lung cancer.



The Lung Cancer Initiative's mission is to advance survivorship and provide support to those affected by lung cancer through research, education and access programs.



**Jacob Kaufman,**  
**MD, PhD**  
Duke University  
2018 Research Fellow

*"LCI is an incredible resource to promote lung cancer research in our state. It helped to launch my career as a lung cancer researcher and to discover novel science that I hope will benefit patients."*

### Research outcomes

- I have identified a novel subset of lung cancer patients whose tumors exhibit unique biologic features making them resistant to immune therapy treatments.
- We have studied mechanisms of immune resistance pertinent to these tumors with a goal of identifying new treatment targets that could allow an effective immune response.

### Career highlights

- Authored eight manuscripts
- Presented at five national and international conferences
- Awarded \$200,000 in additional lung cancer research funding

*"Dr. Kaufman is a promising early career physician scientist studying an important molecular variant of lung cancer. He will continue his career as a faculty research scientist at the prominent Ohio State University Cancer Center. The Lung Cancer Initiative provided Dr. Kaufman with funding early in his career that was critical to launching his research program." – Neal Ready, MD, PhD*